You are here: Industry Insights > Lilly

News List

Lilly considering spinning out or entirely selling the animal health business pharmafile
October 26, 2017
Eli Lilly released its Q3 financials and the major talking point was the announcement that the business was reviewing “strategic alternatives” for its Elanco Animal Health unit.
Lilly teams up with CureVac in $1.8 billion cancer vaccine partnership pharmafile
October 20, 2017
Eli Lilly has announced it is to partner up with CureVac to leverage its proprietary RNActive technology in order to develop and commercialise up to five cancer vaccine products.
Lilly, CureVac pen $1.8B mRNA cancer vaccine deal fiercebiotech
October 19, 2017
Lilly is making a $50 million upfront payment and €45 million equity investment to get the deal up and running.
Lilly under legal fire over split from Adocia biospectrumasia
October 17, 2017
Lyon has begun arbitration proceedings against Lilly about nine months after the Big Pharma walked away from the deal it struck in 2014
Lilly’s Verzenio misses key survival goal in lung cancer pharmatimes
October 12, 2017
Eli Lilly’s breast cancer drug Verzenio has failed to improve overall survival in a late-stage study assessing the drug’s potential in patients with KRAS-mutated, advanced non-small lung cancer (NSCLC).
Lilly steps up to rival Pfizer, Novartis with Verzenio breast cancer approval fiercepharma
September 29, 2017
For the second time in just over six months, there’s a newcomer in a next-generation class of breast cancer-fighters.
Lilly/Incyte's baricitinib musters mixed data in atopic dermatitis trial fiercebiotech
September 18, 2017
In a phase 2 atopic dermatitis trial, Eli Lilly and Incyte's baricitinib hit its primary endpoint but missed a secondary objective, prompting unfavorable comparisons with Sanofi and Regeneron's recently approved Dupixent.
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting po fiercepharma
September 14, 2017
Meanwhile, after unveiling its own cardiovascular outcomes data at ADA, rival Johnson & Johnson will have subanalyses of its own to present later in the week.
Lilly's Cyramza combo boasts strong results in bladder cancer pharmafile
September 12, 2017
Eli Lilly has announced new Phase 3 data at the European Society for Medical Oncology 2017 Congress which further add to the efficacy profile of Cyramza in treating platinum-refractory advanced urothelial carcinoma when used in combination with docetaxel.
Lilly to shutter U.S., China R&D centers fiercebiotech
September 08, 2017
As part of a major series of global cuts across its divisions, Eli Lilly is putting two research centers on the chopping block.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page